Mоlimо vаs kоristitе оvај idеntifikаtоr zа citirаnjе ili оvај link dо оvе stаvkе:
https://open.uns.ac.rs/handle/123456789/16293
Nаziv: | Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid | Аutоri: | Mooranian, A. Zamani, N. Momir Mikov Svetlana Goločorbin-Kon Stojanović, Goran Arfuso, F. Al-Salami, H. |
Ključnе rеči: | probucol;Microencapsulation;Deoxycholic acid | Dаtum izdаvаnjа: | 23-авг-2018 | Prојеkаt: | MEDLEM | Čаsоpis: | Therapeutic Delivery | Sažetak: | Aim: Deoxycholic acid (DCA) has improved gliclazide oral absorption, while Eudragit® (ED) polymers have improved formulation stability of antidiabetic drugs. The aim of the study is to test if DCA and ED encapsulation will optimize the release and stability of the potential antidiabetic drug probucol (PB). Materials & methods: The PB formulations were prepared using ED polymers and DCA, and formulations were analyzed for their rheological and biological properties. Results: Rheological properties and size distribution were similar among all groups. ß-cell survival and biological activities were best with NM30D microcapsules. The inflammatory profile and oxidative stress effects of microcapsules remained similar among all groups. Conclusion: ED NM30D and DCA incorporation can exert positive and stabilizing effects on PB oral microcapsules | URI: | https://open.uns.ac.rs/handle/123456789/16293 | ISSN: | 2041-5990 | DOI: | 10.4155/tde-2018-0036 | Prаvа: | Attribution-NonCommercial-ShareAlike 3.0 United States |
Nаlаzi sе u kоlеkciјаmа: | FTN Publikacije/Publications |
Dаtоtеkе u оvој stаvci:
Dаtоtеkа | Оpis | Vеličinа | Fоrmаt | |
---|---|---|---|---|
Eudragit®-based microcapsules of probucol.pdf | 401.48 kB | Adobe PDF | Pоglеdајtе |
Prеglеd/i stаnicа
36
Prоtеklа nеdеljа
0
0
Prоtеkli mеsеc
0
0
prоvеrеnо 15.03.2024.
Prеuzimаnjе/а
10
prоvеrеnо 15.03.2024.
Google ScholarTM
Prоvеritе
Аlt mеtrikа
Оvа stаvkа је licеncirаnа pоd Krеаtivnа dоzvоlа grаđаnа